WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the ...
Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical improvements were observed among key secondary ...
AstraZeneca’s SAPHNELO ® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector, the SAPHNELO Pen , for the treatment of adult patients with systemic ...
Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ...
EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced positive data on enpatoran, an investigational, oral, novel TLR7/8 inhibitor, ...
Dear Dr. Roach: What is lupus, and what does it do to your body? I just had a friend diagnosed with it after many months of tests. — T.S.B. Dear T.S.B.: The term "lupus" generally means systemic lupus ...
Dapirolizumab pegol demonstrated significant efficacy in reducing fatigue and disease activity in systemic lupus erythematosus patients during the PHOENYCS GO study. Dapirolizumab pegol (DZP), a novel ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results